Cipla on Wednesday announced the launch of Cippoint, a diagnostic device for various conditions including Infectious diseases, diabetes, and thyroid function.
Cippoint- a point-of-care testing device offers a wide range of testing parameters including cardiac markers, fertility, diabetes, thyroid function, infectious diseases, inflammation, metabolic markers, and coagulation markers, the Mumbai-based drug maker said in a statement.
The device has been approved by the European In-Vitro Diagnostic Device Directive, ensuring reliable testing solutions.
Cippoint will enable the doctors to get the test results in 3 to 15 minutes, enabling a faster clinical decision-making process.
Cippoint also has an Automated system and user-friendly interface that will allow the usage of the device even in rural areas and remote areas with limited infrastructure, Cipla said.
“We are actively working towards delivering innovative solutions that enable prompt and effective diagnosis, thereby plugging gaps in the diagnostic ecosystem. This development further strengthens our vision of supporting patients across the healthcare continuum,” Cipla One India Business CEO Achin Gupta said.
The company said that with the launch of the device the company is expanding its product offerings for diagnostic laboratories and by providing reliable and accurate test solutions at an affordable price, it is aiming in bridging the gap in the diagnostic ecosystem in India.
